What Histalon Treats: Main Uses and Benefits

Histalon, an H2 receptor antagonist, is used primarily to help reduce the production of stomach acid in various common and complex gastrointestinal conditions. This reduction in acid supports the body's natural processes, including the maintenance of the lining of the esophagus and stomach, and may help alleviate painful symptoms. This class of medicine is used to manage symptoms associated with gastroesophageal reflux disease (GERD) and conditions such as gastric or duodenal ulcers.

The use of this medication aims to offer benefit to the patient, as this class of medication is intended to support comfort through the management of acid-related irritation. The management of acid secretion is a primary goal in treating conditions like gastroesophageal reflux disease. Histalon is also utilized for managing conditions of excessive acid production, including gastric hypersecretion and Zollinger-Ellison syndrome. The common symptoms it helps relieve are heartburn, acid indigestion, and sour stomach.

Quick Fact: May assist in the management of heartburn

Regulatory References

1. NIH MedlinePlus overview of H2 Blockers

Who Can and Cannot Use Histalon?

This section outlines the population eligibility and non-eligibility rules for Histalon (Chlorphenamine Maleate), strictly based on official regulatory labeling. Eligibility is defined by age, pre-existing health conditions, and current treatments.

Eligibility Scope

Status	Population Group
Allowed	Adults and children aged 12 years and over are approved for standard use. Children aged 6 to under 12 years are approved for conditional use at a reduced dose.
Contraindicated	Use is strictly prohibited for patients with known hypersensitivity to chlorpheniramine, those taking MAOI therapy or within 14 days of cessation, and individuals with narrow-angle glaucoma or urinary retention.
Not Recommended	Use is generally not recommended for children under 6 years and for women during the third trimester of pregnancy or while breastfeeding.

Condition-Specific Restrictions

Official labeling requires caution or professional consultation for patients with severe hepatic impairment, renal impairment, seizure disorders, and certain chronic respiratory conditions such as COPD. Use is also restricted by the presence of severe cardiovascular disease or gastrointestinal obstruction. Older adults may require special consideration due to increased susceptibility to effects.

Histalon (Chlorphenamine Maleate) has officially documented interaction patterns that primarily involve pharmacodynamic potentiation and metabolic inhibition, as established in regulatory labeling. The combination of Histalon with certain medicines and substances is restricted or prohibited due to these effects.

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated (prohibited) according to official regulatory information. This restriction extends to a mandatory separation period, meaning Histalon must not be used within fourteen days (14 days) of discontinuing MAOI therapy.

Drug–Drug and Drug–Substance Interactions

Interaction Type	Interacting Substance/Class	Official Interaction Outcome
Metabolic/Exposure	Phenytoin	Histalon inhibits the metabolism of phenytoin, which leads to increased plasma concentration and risk of phenytoin toxicity (1.3).
Pharmacodynamic	CNS Depressants (Opioids, Hypnotics, Sedatives, Anxiolytics)	Co-administration may result in additive CNS depression (1.3).
Pharmacodynamic	Anticholinergic Agents	The anticholinergic properties are intensified when co-administered (1.3).
Drug–Substance	Alcohol (Ethanol)	The effects of alcohol may be increased, and concurrent use must be avoided (1.3).

Population-Specific Interaction Notes

Official labeling notes that Elderly Patients are more susceptible to the neurological anticholinergic effects of Histalon. Furthermore, caution is required for patients with Hepatic Impairment due to the risk of drug accumulation.

Mechanism of Action: How Histalon Works

---

Histalon functions as a highly selective competitive antagonist of the histamine H3 receptor ( H3 R). This receptor is primarily located on the presynaptic membranes of histaminergic neurons, where it acts as an autoreceptor, controlling the synthesis and release of histamine.

The binding of Histalon to the H3 R blocks the receptor's inhibitory signaling cascade within the neuron. This leads to the disinhibition of the autoreceptor, resulting in a subsequent increase in histamine synthesis and release into the synaptic cleft. This up-regulation of histamine represents the primary molecular and cellular cascade.

This increased synaptic histamine can lead to allosteric modulation of other central neurotransmitter systems, specifically the cholinergic ( ACh) and gamma-aminobutyric acid ( GABA) pathways. The resulting alteration in the balance of these neurotransmitter systems constitutes the system-level physiological consequence within the central nervous system.

How to Use Histalon: Official Administration Guidelines

Histalon (Chlorphenamine Maleate) is administered according to standardized regimens. The medicine is primarily used for short-term, symptomatic relief, and continuous use beyond two weeks is not generally indicated without further professional review.

---

Administration Routes and Forms

The medication is available in several official forms for two principal routes of administration. The oral route is used for common formulations, including immediate-release (IR) tablets (e.g., 4 mg), extended-release (ER) tablets or capsules (e.g., 8 mg or 12 mg), and syrup/oral solution. For acute, time-sensitive situations, the medicine can be administered via the parenteral route as an injection (10 mg/mL) through intravenous (IV), intramuscular (IM), or subcutaneous (SC) injection.

---

Standard Dosing Principles

Patient Group	Standard Dosing Regimen	Maximum Daily Dose
Adults (IR Oral)	4 mg every 4 to 6 hours	24 mg
Older Adults	4 mg every 6 to 8 hours (or lower)	12 mg
Children (6-12 years)	2 mg every 4 to 6 hours	12 mg

Frequency and Timing: Immediate-release forms require a minimum dosing interval of four hours. Extended-release forms are typically taken once or twice daily. Oral forms may be ingested with or without food. Extended-release tablets and capsules must be swallowed whole and should not be crushed, chewed, or divided. If a dose is missed, it should be skipped if it is near the time for the next scheduled dose, and the patient should resume the regular schedule without doubling the amount.

Research evidence / Overview of studies for Histalon

Evidence for Use in Allergic Rhinitis and General Allergies

Research has examined Histalon's profile in studies exploring how symptoms change over time in conditions such as seasonal and perennial allergic rhinitis, which are conditions characterized by fluctuating or episodic manifestations. Research has primarily employed Randomized Controlled Trials (RCTs) to explore how symptoms change over time. These studies involved healthy adults and people diagnosed with varying degrees of allergy symptoms. Studies explored the patterns of symptom change observed in the studies, which often focused on short-term or episodic symptom patterns. Research highlights changes measured during the study period, particularly within the initial hours and days following administration. Studies also explored the time required before changes in symptoms were noted. Furthermore, evidence contributes to understanding symptom patterns by detailing the medicine's pharmacokinetic profile, which is how the body processes the drug, across different oral forms such as tablets and liquid.

Evidence for Use in Pruritus (Itching) and Urticaria (Hives)

The medicine was also evaluated in research that examined its profile in conditions associated with acute or disruptive episodes, such as pruritus (itching) and urticaria (hives). Studies monitored the drug in situations of heightened symptom activity, using controlled trials that sometimes included comparisons against other treatments. The outcomes related to systemic or functional imbalance were monitored through skin tests, which track changes in reactions like wheal and flare. The evidence base includes descriptive research findings, contributing to the broader evidence landscape related to episodic changes.

Key Evidence Gaps and Areas of Uncertainty

Clinical trials conducted for Histalon are relevant in trials assessing short-term or episodic symptom patterns, indicating that follow-up durations were often short. The research provides insight into short-term changes, but there is limited information for long-term outcomes or maintenance use. Research has specifically examined the medicine in certain subgroups, such as children and adolescents, but comparative evidence is lacking for direct, recent head-to-head comparisons against newer antihistamines currently available. Findings were mixed in some trials when comparing the drug's activity as measured by laboratory skin tests versus the duration of symptom relief reported by the patients themselves. The evidence describes group patterns, but research does not determine whether an individual will respond similarly, and long-term effects are not fully established.

Key Studies & References Chlorpheniramine (Oral Route) Drug Information – A comprehensive drug monograph

Common questions about Histalon (FAQ)

Q: Can Histalon cause a change in mood or energy levels?

Official safety documents state that central nervous system side effects are possible. These can include fatigue, irritability, confusion, and disturbance in attention, which may be experienced as changes in mood or energy levels. Official safety information notes that paradoxical excitation (such as restlessness or agitation) has also been reported, particularly in certain populations.

Q: Do I need to take Histalon at the exact same time every day?

Official guidance primarily specifies the minimum time interval required between doses, particularly for immediate-release forms. While taking the medication at a consistent time may support adherence to the schedule, regulatory instructions primarily focus on respecting the minimum required hours between doses.

Q: Will Histalon affect my ability to drive or operate machinery?

Yes, official safety warnings indicate that Histalon may cause drowsiness, dizziness, and blurred vision. Due to the possibility of these effects, regulatory guidance notes that people should avoid driving or operating heavy machinery until they understand the medication's effects.

Q: What does it mean if the official documentation describes Histalon as an 'H-receptor modulator'?

The official mechanism of action describes Histalon as a competitive H1-receptor antagonist and an H3-receptor blocker. This action causes a disinhibition of histamine neurons, leading to increased histamine release, which modulates (or adjusts) the activity of other chemical systems in the brain.

Q: Does the time of day I take Histalon matter?

Because drowsiness is listed as a very common side effect, official patient information often indicates that taking the dose before bedtime may help to mitigate the potential impact of sedation during daytime activities.

Q: Are there any skin-related side effects linked to Histalon?

Official adverse reaction reports list several skin-related effects. These include skin rash, hives (itchy welts), and swelling. Additionally, severe but rare effects, such as anaphylactic reactions (a severe allergic reaction), are noted in the safety profile.

Q: How does the dosage strength of Histalon relate to its effects?

The regulatory dose-response profile indicates that higher doses are linked to a longer duration of symptom relief, as seen in extended-release forms. However, official documentation also notes that the incidence and intensity of dose-dependent side effects, like sedation, may increase with higher strength.

Q: What is the difference between the immediate-release and extended-release versions of Histalon?

According to official labeling, the immediate-release (IR) version provides relief for a shorter period and requires taking a dose approximately every 4 to 6 hours. The extended-release (ER) version is formulated to release the medication over a longer period, resulting in a dosing frequency of once or twice per day.

Q: How long does Histalon stay in your system?

The elimination half-life of the drug—the time it takes for half of the medication to be cleared from the body—is highly variable. Official pharmacokinetic data reports this range to be approximately 12 to 43 hours in adults following a single dose.

Q: Can Histalon be taken with common pain relievers like ibuprofen?

Based on regulatory drug interaction databases, a direct interaction between single-ingredient Histalon and common nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen is not typically listed. However, official drug information requires that patients inform a healthcare professional about all medications, including over-the-counter pain relievers.

Q: Is there a generic version of Histalon available?

Yes, Histalon, whose active ingredient is Chlorphenamine Maleate, is widely available as a generic medication. Regulatory bodies track and approve these generic versions for use.

Q: Are there specific vitamins or supplements that should be avoided while taking Histalon?

Official drug information provides specific warnings against using alcohol and other central nervous system (CNS) depressants due to additive effects. Official guidance directs patients to inform a healthcare professional about all supplements, including herbal or vitamin supplements.

Q: Is Histalon habit-forming?

No. Histalon is not considered to be habit-forming. The active ingredient is not classified as a controlled substance by U.S. regulatory authorities.

Q: Can Histalon affect blood pressure readings?

According to official adverse event reports, Histalon has been associated with changes in blood pressure. Both high blood pressure (hypertension) and low blood pressure (hypotension) have been noted in the safety documentation.

Q: Does Histalon have a 'black box warning' in official FDA documents?

No. The single active ingredient of Histalon (Chlorphenamine Maleate) does not carry a Black Box Warning in official FDA labeling. This type of warning is reserved for the most serious safety issues.

Q: Is Histalon classified as a controlled substance?

No. Histalon is not classified as a controlled substance by regulatory authorities in the United States. Controlled substance classification relates to the drug's potential for abuse or dependence.

Histalon (Chlorphenamine Maleate) must be stored strictly according to official regulatory guidelines to maintain its stability.

Storage Conditions

Store the medication at controlled room temperature, typically between 20mathrmC and 25mathrmC (68mathrmF to 77mathrmF). It is essential to protect the product from moisture and light by keeping it in its original container with the lid tightly closed. You must protect the medicine from freezing; freezing is prohibited as it can compromise the formulation. Liquid forms may have a limited shelf-life after opening.

Disposal and Safety

All Histalon products must be kept out of the sight and reach of children. Unused or expired medicine should not be flushed down the toilet or poured into a drain. Regulatory guidance recommends disposal through a medicine take-back program or following specific local instructions for pharmaceutical waste.